key: cord-0692616-p1tjl67p authors: Lino, Katia; Alves, Lilian S.; Raposo, Jessica V.; Medeiros, Thalia; Souza, Cintia F.; da Silva, Andrea A.; de Paula, Vanessa S.; Almeida, Jorge R. title: Presence and clinical impact of human herpesvirus‐6 infection in patients with moderate to critical coronavirus disease‐19 date: 2021-10-19 journal: J Med Virol DOI: 10.1002/jmv.27392 sha: d850a9fa16f35d853feafc01e9d1f400567c346d doc_id: 692616 cord_uid: p1tjl67p Human herpesvirus‐6 (HHV‐6) may cause serious diseases in immunocompromised individuals. SARS‐CoV‐2/HHV‐6 coinfection has been emphasized in previous works, mostly case reports, small series, or epidemiological studies, but few are known about its real clinical outcomes. Here we present a real‐world pilot study aiming to understand the frequency and the clinical impact of HHV‐6 coinfection in moderate to critically ill patients hospitalized due to COVID‐19. SARS‐CoV‐2 and HHV‐6 were evaluated in nasopharyngeal samples at the hospital admission of suspected COVID‐19 patients. From 173 consecutive cases, 60 were SARS‐CoV‐2 positive and 13/60 (21.7%) were HHV‐6 positive after identified as the HHV‐6B species by a Sanger sequencing. The SARS‐CoV‐2+/HHV‐6+ group was younger but not significant for cardiovascular diseases, diabetes, obesity, and cancer, but significant among therapeutic immunosuppressed patients (as systemic lupus erythematosus and kidney transplant patients). In the medical records, only sparse data on cutaneous or neurological manifestations were found. Biochemical and hematological data showed only a trend towards hyperferritinemic status and lymphopenia. In conclusion, despite the impressive high frequency of HHV‐6 coinfection in SARS‐CoV‐2 positive cases, it did not impact general mortality. We suggest larger future prospective studies to better elucidate the influence of HHV‐6 reactivation in cases of COVID‐19, designed to specific assessment of clinical outcomes and viral reactivation mechanisms. microangiopathy. 3 HHV-6 DNA can be detected in saliva and in the nasal mucosa, 4 and in general, viral reactivation has been reported as asymptomatic, but in cases of advanced age and/or state of immunosuppression, it may be associated with cases of encephalitis, cutaneous manifestations (pityriasis rosea) and Kawasaki disease; the latter mainly in children. 5 Recently, HHV-6 reactivation in patients with COVID-19 has been associated with some clinical presentations, including pityriasis rosea and Kawasaki disease. 6 HHV-6 was discovered in 1986 and initially named B-lymphotropic virus human, as it is mainly found infecting and replicating in lymphocytes of the cell lineage. As with all herpesviruses, HHV-6 infection can be asymptomatic and pass unnoticed, but the virus can remain latent until a deficiency host immune system favors its reactivation. After primary infection, HHV-6 is capable of establishing lifelong persistence by the involvement of different stages of the viral life cycle, and it is also capable of reactivation, meaning the active production of detectable mature virions in some body tissues/ compartments. 7 HHV-6 are classified into two closely related groups that have been termed variants A (HHV-6A) and B (HHV-6B) and now originated as distinct species of herpesviruses. HHV-6B is the 13 major causative agents of sudden exanthema, yet with few studies, a disease has not been defined as associated with HHV-6A. 8 Primary infection with HHV-6B is extremely common and usually occurs in early childhood. The most common symptom is a high fever, and although the course is usually benign, some may develop encephalitis. 9, 10 For unknown reasons, the frequency of neurological complications varies by geography, being much higher in Japan than in the United States. 10 The epidemiology of HHV-6A is poorly charged. When compared to HHV-6B, a primary infection must occur later in life in Europe, America, and Asia; in sub-Saharan Africa, contrasting data on the prevalence of HHV-6A infection in infants have been reported. [11] [12] [13] Viral coinfections in COVID-19 patients are an emergent issue. 14 SARS-CoV-2 virus, through viral replication mechanisms and immune-inflammatory disturbance, could play a role, triggering HHV-6 reactivation. 15 Moreover, COVID-19 patients also frequently present lymphopenia, which may favor this mechanism. 16 RT-qPCR protocols. The qPCR reaction for HHV-6 was performed using a primer and probe sequences for the U56 region of HHV-6. 17 To investigate the active infection, the HHV-6 detection was performed in the same samples used to detect SARS CoV-2, for this reason, the RNA ex- Thus, we performed the PCR of these samples using primer sequences previously described, 18 with the sequences obtained by sequencing aligned by the Bioedit software. For analysis, patients were divided into two groups: coinfection (SARS-CoV-2(+)/HHV-6(+)) and without coinfection (SARS-CoV-2(+)/ HHV-6(−)) groups. We compared variables such preexisting conditions were expressed as mean ± standard deviation (SD) or n (%). Differences between groups were assessed using the χ 2 and Mann-Whitney tests, according to variables characteristics, continuous or categorical. For analyses, we used a statistical package (SPSS) and were considered significant when p < 0.05. The 61.5%), diabetes (n = 8; 61.5%), therapeutic immunosuppression status (n = 6; 38.5%). We also observed clinical outcomes as the need for mechanical ventilation, acute kidney injury, and sepsis (n = 9 each, 69.2%). Four (30.7%) patients died. Table 1 shows clinical and laboratory characteristics of patients with and without HHV-6 associated co-infections. The blood samples for those diagnoses tests were obtained not exceeding the fifth day of hospitalization. In spite of such a high prevalence of HHV-6 DNA found (21.7%), there was only scarce data about cutaneous or neurological manifestations in the medical records, including the emergence and intensive care units. Furthermore, in a more detailed analysis of Table 1 , considering the group of patients with coinfection for comparison, we did not find statistical differences between the groups for any of the studied variables, except for the use of therapeutic immunosuppression (p = 0.01). The coinfection group tended to be younger and also to have higher levels of ferritin and leukopenia, but these were not statistically significant. It is noteworthy that we found no differences 19 All 13 positive cases of HHV-6 were identified as HHV-6B species. In addition, our aim was also to assess the role of some clinical risk comorbidities and in-hospital outcomes, including mortality, and we were able to demonstrate a significant relationship only with prior therapeutic immunosuppression (as we can see in SLE and kidney transplant patients, for example). Besides, trying to create some relation with cutaneous or neurological manifestations, we realized that this information was very poorly described in medical records and we discuss this. A very important issue is that herpesvirus reactivation has been reported to be very common in critically ill patients even before the COVID-19 pandemic, [19] [20] [21] as well as in cancer, autoimmune diseases, and organ transplantation. 1, 22 Guidelines exist in this setting to actively monitor and address them, including therapeutic options, from vaccines to antiviral drugs, ranging from cytomegalovirus (CMV), Epstein-Barr virus (EBV), varicella-zoster virus, and the herpesviridae family, in general. About the presence of HHV-6 in these cases, some clinical outcomes, severity, and prognostic follow-up have already been suggested, but much still needs to be known and how to measure its consequences. In this study, a high incidence rate was found (21.7%), RNA was extracted from nasopharyngeal swabs, and On the other hand, skin lesions, for example, pityriasis rosea due to HHV-6B reactivation, in moderate to critically ill patients might not be properly valued and could not even be properly described in medical reports. Perhaps skin lesions could help to indicate coinfection with SARS-CoV-2 and some viruses of the herpes family. In addition, aware that in immunosuppressed severely ill patients, sometimes sedated and intubated, HHV-6 can trigger encephalitis, we should always have in mind its presumptive diagnosis. 28 This approach is often hidden by these common situations in critical units. As well, in some centers, there could be some difficulty in performing a lumbar puncture and even taking patients to computed tomography (CT) or magnetic resonance imaging (MRI) room, for example. That is an important reason for documenting the presence of coinfection with HHV-6/SARS-CoV-2, which may determine changes in the therapeutic approach of the patient and an improvement in prognosis since usually ganciclovir and foscarnet isolated or in combination are indicated to treat HHV-6 encephalitis. 29 About COVID-19 patients and intensive care outcomes, a recent study using DNAemia positivity for EBV, CMV, and HHV-6 was associated only with longer ICU length-of-stay, 19 while other study using tracheal aspirates in a longitudinal way observed the same. 20 Regarding risk factors, we found a significant relationship in patients using therapeutic immunosuppression, as already mentioned. We have not found an impact of the HHV-6 infection in terms of the need for intensive care or even on overall mortality. We believe that we should be attentive and careful with these findings, as we have This study was supported by CAPES (#001), and Brazilian National Re- Beyond cytomegalovirus and Epstein-Barr virus: a review of viruses composing the blood virome of solid organ transplant and hematopoietic stem cell transplant recipients Herpesviruses: harmonious pathogens bute. relevant cofactors in other diseases? Laboratory and clinical aspects of human herpesvirus 6 infections Longitudinal study on oral shedding of human betaherpesviruses 6 and 7 in renal transplant recipients reveals active replication Reactivation of human herpesviruses 6 and 7 in Kawasaki disease The clinics of HHV-6 infection in COVID-19 pandemic: pityriasis rosea and Kawasaki disease Latency, integration, and reactivation of human herpesvirus-6 Identification of human herpesvirus-6 as a causal agent for exanthem subitum Roseoloviruses in transplant recipients: clinical consequences and prospects for treatment and prevention trials Clinical impact of primary infection with roseoloviruses Infection with AIDS-related herpesviruses in human immunodeficiency virus-negative infants and endemic childhood Kaposi's sarcoma in Africa Predominant human herpesvirus 6 variant A infant infections in an HIV-1 endemic region of Sub-Saharan Africa Prevalence and risk factors for betaherpesvirus DNAemia in children >3 weeks and <2 years of age admitted to a large referral hospital in sub-Saharan Africa Viral coinfections in COVID-19 COVID-19, HHV6 and MOG antibody: a perfect storm Human herpesvirus-6, −7, and Epstein-Barr virus reactivation in pityriasis rosea during COVID-19 Multiplex qPCR facilitates identification of betaherpesviruses in patients with acute liver failure of unknown etiology Rapid and simultaneous detection of 6 types of human herpes virus (herpes simplex virus, varicella-zoster virus, Epstein-Barr virus, cytomegalovirus, human herpes virus 6A/B, and human herpes virus 7) by multiplex PCR assay High incidence of Epstein-Barr virus, cytomegalovirus, and human-herpes virus-6 reactivations in critically ill patients with COVID-19 Herpes simplex virus and cytomegalovirus reactivations among severe COVID-19 patients Epidemiology of multiple herpes viremia in previously immunocompetent patients with septic shock Co-reactivation of the human herpesvirus alpha subfamily (herpes simplex virus-1 and varicella zoster virus) in a critically ill patient with COVID-19 Functional exhaustion of antiviral lymphocytes in COVID-19 patients Respiratory microbial co-infection with SARS-CoV-2 Dermatological aspects of SARS-CoV-2 infection: mechanisms and manifestations Cutaneous manifestations in adult patients with COVID-19 and dermatologic conditions related to the COVID-19 pandemic in health care workers Infection mechanism of SARS-COV-2 and its implication on the nervous system Human herpesvirus 6B encephalitis in a liver transplant recipient: a case report and review of the literature Viral encephalitis: a practical review on diagnostic approach and treatment The authors declare that there are no conflict of interests. All authors have contributed substantially to this manuscript. Katia Lino, Lilian S. Alves, Andrea A. da Silva, and Jorge R. Almeida con- The data that support the findings of this study are available from the corresponding author upon reasonable request.